ETFs Gain Attention Amid FDA Drug Alerts and Eli Lilly Developments
Investors are focusing on healthcare ETFs as Eli Lilly expands its treatment portfolio, balancing risks and growth opportunities.
The recent warning from the FDA regarding vision loss associated with certain medications has sparked interest in sector-focused exchange-traded funds (ETFs), particularly in the healthcare domain. While the risk of vision loss for users of GLP-1 medications is quite low—estimated at less than 1%—the market dynamics remain favorable for pharmaceutical firms, especially those like Eli Lilly (LLY).
Understanding the Risks and Benefits
The FDA warning reflects a genuine concern, yet it should not overshadow the significant advantages that these drugs may offer. Notably, GLP-1 medications provide considerable cardiovascular and metabolic benefits, which might outbalance the potential risks. Long-term demand for diabetes and endocrine treatments is expected to sustain or even grow, enhancing the revenue outlook for companies developing these therapies.
The Broader Investment Perspective
It's important for investors to look beyond the surface. Eli Lilly is not solely focused on obesity treatments. The company is also seeing growth in its immunology, oncology, and neuroscience divisions. For instance, Jaypirca is becoming a leading BTK inhibitor in the U.S., and aKisunla is positioning itself in the Alzheimer's treatment space.
For those looking at long-term investments, the outlook for GLP-1 therapies remains robust. However, diversifying within the healthcare sector could provide a more comprehensive investment approach, capturing growth in both obesity therapies and established, stable healthcare businesses.
Healthcare ETFs Worth Considering
For investors wishing to capitalize on the ongoing growth in metabolic health while minimizing company-specific risks, several diversified healthcare and pharmaceutical ETFs present attractive options. These funds not only provide exposure to Eli Lilly but also spread investments across various sectors like oncology, immunology, and cardiovascular treatments.
- iShares U.S. Pharmaceuticals ETF (IHE)
- Assets: $1.71 billion
- Constituents: 52 pharmaceutical companies
- LLY's Weight: 26.29%
- Year-to-Date Performance: +30.2%
- Expense Ratio: 0.37%
- VanEck Pharmaceutical ETF (PPH)
- Assets: $1.09 billion
- Constituents: 26 pharmaceutical companies
- LLY's Weight: 22.79%
- Year-to-Date Performance: +17.8%
- Expense Ratio: 0.36%
- State Street Health Care Select Sector SPDR ETF (XLV)
- Assets: $50.54 billion
- Constituents: 61 healthcare companies
- LLY's Weight: 16.54%
- Year-to-Date Performance: +22%
- Expense Ratio: 0.08%
- Vanguard Health Care ETF (VHT)
- Assets: $20.8 billion
- Constituents: 412 healthcare-related companies
- LLY's Weight: 12.93%
- Year-to-Date Performance: +21.2%
- Expense Ratio: 0.09%
As the healthcare landscape continues to evolve, these ETFs present opportunities for investors to engage with the growing market while managing potential risks.